Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEAMERICAN:BTG NASDAQ:IRWD NYSE:RIG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTGB2Gold$4.66-2.1%$4.70$3.31▼$6.28$6.34B0.6123.99 million shs21.20 million shsIRWDIronwood Pharmaceuticals$3.29-5.1%$3.80$0.56▼$5.78$582.12M0.252.72 million shs1.70 million shsRIGTransocean$6.34+1.1%$6.54$2.47▼$7.66$6.91B1.3433.85 million shs31.35 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTGB2Gold-2.10%+1.75%+6.88%-15.12%+38.69%IRWDIronwood Pharmaceuticals-3.08%-11.73%-22.07%-4.95%+473.42%RIGTransocean+1.21%-7.94%-8.34%+2.79%+151.61%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTGB2Gold$4.66-2.1%$4.70$3.31▼$6.28$6.34B0.6123.99 million shs21.20 million shsIRWDIronwood Pharmaceuticals$3.29-5.1%$3.80$0.56▼$5.78$582.12M0.252.72 million shs1.70 million shsRIGTransocean$6.34+1.1%$6.54$2.47▼$7.66$6.91B1.3433.85 million shs31.35 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTGB2Gold-2.10%+1.75%+6.88%-15.12%+38.69%IRWDIronwood Pharmaceuticals-3.08%-11.73%-22.07%-4.95%+473.42%RIGTransocean+1.21%-7.94%-8.34%+2.79%+151.61%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTGB2Gold 2.00HoldN/AN/AIRWDIronwood Pharmaceuticals 2.43Hold$6.2389.75% UpsideRIGTransocean 2.00Hold$6.969.93% UpsideCurrent Analyst Ratings BreakdownLatest BTG, IRWD, and RIG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2026RIGTransocean BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$6.00 ➝ $8.005/6/2026RIGTransocean TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$5.50 ➝ $6.004/27/2026IRWDIronwood Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)4/21/2026RIGTransocean Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/15/2026RIGTransocean Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$5.00 ➝ $7.004/7/2026RIGTransocean SusquehannaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetPositive$7.50 ➝ $8.003/19/2026RIGTransocean Clarkson CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 6/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTGB2Gold$3.06B2.03$0.77 per share6.06$2.72 per share1.71IRWDIronwood Pharmaceuticals$296.15M1.81$0.24 per share13.87($1.61) per share-2.04RIGTransocean$4.14B1.71$0.69 per share9.16$7.36 per share0.86Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTGB2Gold$401.91M-$0.0312.944.240.4514.91%21.36%13.13%8/6/2026 (Estimated)IRWDIronwood Pharmaceuticals$24.02M$0.605.59N/AN/A28.26%-39.65%26.54%8/6/2026 (Estimated)RIGTransocean-$2.92B-$2.98N/A25.34N/A-66.79%0.88%0.46%8/3/2026 (Estimated)Latest BTG, IRWD, and RIG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026IRWDIronwood Pharmaceuticals$0.2467$0.24-$0.0067$0.24$92.11 million$106.51 million5/6/2026Q1 2026BTGB2Gold$0.11$0.19+$0.08N/A$893.41 million$1.16 billion5/4/2026Q1 2026RIGTransocean$0.07-$0.03-$0.10$0.06$1.02 billion$1.08 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBTGB2Gold$0.081.72%N/AN/A N/AIRWDIronwood PharmaceuticalsN/AN/AN/AN/AN/ARIGTransocean$0.609.47%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBTGB2Gold0.131.190.59IRWDIronwood PharmaceuticalsN/A1.411.41RIGTransocean0.601.541.20Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTGB2Gold61.40%IRWDIronwood PharmaceuticalsN/ARIGTransocean67.73%Insider OwnershipCompanyInsider OwnershipBTGB2Gold1.18%IRWDIronwood Pharmaceuticals9.30%RIGTransocean9.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBTGB2Gold6,3271.33 billion1.32 billionNot OptionableIRWDIronwood Pharmaceuticals220163.06 million147.89 millionOptionableRIGTransocean5,6001.12 billion1.01 billionOptionableBTG, IRWD, and RIG HeadlinesRecent News About These CompaniesTD Cowen Raises Transocean (RIG) Price Target After Q1 ResultsMay 28, 2026 | finance.yahoo.comOilfield Services Stocks Q1 In Review: Transocean (NYSE:RIG) Vs PeersMay 28, 2026 | finance.yahoo.comOilfield services stocks Q1 in review: Transocean (NYSE:RIG) vs peersMay 28, 2026 | msn.comTransocean Ltd. $RIG Shares Purchased by HighTower Advisors LLCMay 27, 2026 | marketbeat.comTransocean Equinox Redeployment Puts Otway Utilization And Valuation In FocusMay 26, 2026 | finance.yahoo.comTransocean: Backlog, Valaris And 2027 Tightness Can Drive The Next LegMay 26, 2026 | seekingalpha.comA Look At Transocean (RIG) Valuation As Shares Deliver Strong Year-To-Date GainsMay 25, 2026 | finance.yahoo.comQ2 Earnings Forecast for Transocean Issued By Zacks ResearchMay 25, 2026 | americanbankingnews.comTransocean Ltd. (NYSE:RIG) Receives Consensus Recommendation of "Hold" from BrokeragesMay 23, 2026 | americanbankingnews.comFideuram Intesa Sanpaolo Private Banking S.P.A. Makes New $2.34 Million Investment in Transocean Ltd. $RIGMay 21, 2026 | marketbeat.comAlibaba, NextEra Energy, Transocean and a real estate stock on CNBC's 'Final Trades'May 20, 2026 | msn.comTed Oakley Says Wall Street Is Chasing The AI 'Dream' While Ignoring 'Mispriced' Energy StocksMay 20, 2026 | benzinga.comTransocean Signs Governance Support Pact Amid Valaris DealMay 19, 2026 | tipranks.comTransocean, Nabors Industries, and Valaris shares skyrocket, what you need to knowMay 18, 2026 | msn.comRIG, FCEL, and ZS: 3 Stocks Making Outsized Moves TodayMay 18, 2026 | schaeffersresearch.comChevron's CEO Just Warned of Physical Oil Shortages. This $6 Offshore Driller Is Up 171% and Still Trades Below Book ValueMay 18, 2026 | 247wallst.comTransocean (RIG) Is Up 6.3% After Swing to Profit on Record Dayrates and New ContractsMay 14, 2026 | finance.yahoo.comIs It Too Late To Consider Transocean (RIG) After Its 138% One Year Rally?May 14, 2026 | finance.yahoo.comTransocean Backlog And Uptime Progress Contrast With EPS MissMay 13, 2026 | finance.yahoo.comTransocean’s Q1 Earnings Call: Our Top 5 Analyst QuestionsMay 13, 2026 | finance.yahoo.comState of New Jersey Common Pension Fund D Makes New $2.16 Million Investment in Transocean Ltd. $RIGMay 10, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026SpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026A Quantum Shift: Why Speculative Money Is Ditching AIBy Jeffrey Neal Johnson | May 13, 2026BTG, IRWD, and RIG Company DescriptionsB2Gold NYSEAMERICAN:BTG$4.66 -0.10 (-2.10%) As of 06/1/2026 04:10 PM EasternB2Gold Corp. operates as a gold producer company. It operates the Fekola Mine in Mali, the Masbate Mine in the Philippines, and the Otjikoto Mine in Namibia. The company also has an 100% interest in the Gramalote gold project in Colombia; 24% interest in the Calibre Mining Corp.; and approximately 19% interest in BeMetals Corp. In addition, it has a portfolio of other evaluation and exploration assets in Mali and Finland. The company was incorporated in 2006 and is headquartered in Vancouver, Canada.Ironwood Pharmaceuticals NASDAQ:IRWD$3.28 -0.18 (-5.06%) As of 03:07 PM Eastern This is a fair market value price provided by Massive. Learn more.Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.Transocean NYSE:RIG$6.34 +0.07 (+1.12%) As of 03:08 PM Eastern This is a fair market value price provided by Massive. Learn more.Transocean Ltd., together with its subsidiaries, provides offshore contract drilling services for oil and gas wells worldwide. It contracts mobile offshore drilling rigs, related equipment, and work crews to drill oil and gas wells. The company operates a fleet of mobile offshore drilling units, consisting of ultra-deepwater floaters and harsh environment floaters. It serves integrated energy companies, government-owned or government-controlled energy companies, and other independent energy companies. The company was founded in 1926 and is based in Steinhausen, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dollar General Signals Reversal With 60% Rebound Potential Kohl's Stock Soars After Better-Than-Feared Quarter Credo Technologies Paved a Path to a $300 Price Point MGM Buyout: The House Doesn't Always Win Alphabet's $80 Billion Offering: Worrisome Dilution or AI Confidence? FirstCash Turns Pawn Into a Growth Machine HubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead? Eli Lilly Wins Back CVS Health, Reverting Novo's Advantage Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
